Prosecution Insights
Last updated: July 17, 2026
Application No. 18/698,993

ASSOCIATION OF A FAECALIBACTERIUM PRAUSNITZII STRAIN AND ANTI-PD-1, ANTI-PD-L1 OR ANTI-CTLA-4 ANTIBODIES FOR THE TREATMENT OF CANCER

Final Rejection §112
Filed
Apr 05, 2024
Priority
Oct 15, 2021 — EU 21306448.8 +1 more
Examiner
OGUNBIYI, OLUWATOSIN A
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Exeliom Biosciences
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
7m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
587 granted / 925 resolved
+3.5% vs TC avg
Strong +42% interview lift
Without
With
+41.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
58 currently pending
Career history
977
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
46.1%
+6.1% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
19.7%
-20.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 925 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The amendment filed 5/5/2026 has been entered. Claims 1-11 and 23 have been cancelled. Claims 12, 21-22 and 24-25 have been amended. Claim 28 is new. Claims 12-22 and 24-28 are under examination. Claim Objections Withdrawn The objection to claim 12 is withdrawn in view of the amendment to the claims. The rejection of claims 12-20, 26 and 27 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph (scope of enablement) is withdrawn in view of the amendment to the claims. The rejection of claims 12-18, 21-22, 26 and 28 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, is withdrawn in view of the amendment to the claims. Claim Rejections Maintained The rejection of claims 12-22 and 24-28 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement is maintained. The statement that all restrictions upon public access to the deposit will be irrevocably removed upon the grant of a patent on this application is insufficient as the statement is missing that the deposit will be replaced if viable samples cannot be dispensed by the depository is required. The statement that all restrictions upon public access to the deposit will be irrevocably removed upon the grant of a patent on this application and that the deposit will be replaced if viable samples cannot be dispensed by the depository is required. This requirement is necessary when deposits are made under the provisions of the Budapest Treaty as the Treaty leaves this specific matter to the discretion of each State. Amendment of the specification to recite the date of deposit and the complete name and full street address of the depository is required. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. The rejection of claims 19-20, 24-25 and 27 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention is maintained. The metes and bounds of “association” as used in the claims is vague. How is the F. prausnitzii associated with the immune check point inhibitor? Status of Claims Claims 12-22 and 24-28 are rejected. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLUWATOSIN A OGUNBIYI whose telephone number is (571)272-9939. The examiner can normally be reached IFP. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Allen can be reached at 5712703497. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /OLUWATOSIN A OGUNBIYI/Primary Examiner, Art Unit 1645
Read full office action

Prosecution Timeline

Apr 05, 2024
Application Filed
Mar 10, 2026
Non-Final Rejection mailed — §112
May 05, 2026
Response Filed
Jun 17, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12662515
FUSION PROTEIN COMPRISING BP26 AND ANTIGENIC POLYPEPTIDE
3y 2m to grant Granted Jun 23, 2026
Patent 12661397
ADJUVANT COMPRISING A GLYCOARCHAEOL AND AN IMMUNOSTIMULANT
2y 11m to grant Granted Jun 23, 2026
Patent 12653882
click OMVs
3y 7m to grant Granted Jun 16, 2026
Patent 12653879
OUTER MEMBRANE VESICLES
3y 3m to grant Granted Jun 16, 2026
Patent 12653846
MICROBIOME COMPOSITIONS
2y 10m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+41.8%)
2y 11m (~7m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 925 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month